Meeting on the Mesa 2021 | Treating hematologic malignancies with immunotherapy

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, describes current challenges in using advanced therapies in hematologic malignancies. Whilst immunotherapies including chimeric antigen receptor (CAR) T cell therapies have improved complete response rates in a number of patients across different indications, major development issues remain. Decreasing costs and wait times for patients are hurdles that need to be overcome and safety concerns additionally need to be addressed to improve accessibility by removing the need for tertiary care. This interview took place at Meeting on the Mesa 2021.